Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial

British Journal of Dermatology

Volumn 152, Issue 4, 2005, Pages 758-764

  Ormerod, A D ^a   Shah, S A A ^a   Copeland, P ^a   Omar, G ^a   Winfield, A ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

Immunosuppressant; Psoriasis; Randomized controlled trial; Sirolimus; Therapy; Topical

Indexed keywords

BENZYL ALCOHOL; CD4 ANTIGEN; DECANOIC ACID; MYRISTIC ACID ISOPROPYL ESTER; RAPAMYCIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG SAFETY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE; MALE; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN BIOPSY; SKIN IRRITATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; SIROLIMUS; SKIN; TREATMENT OUTCOME;

EID: 17644374126     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06438.x     Document Type: Article

References (25)

1. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58:373-95.
2. Choi JH, O'Connor TP, Kang S et al. Activation of ribosomal protein S6 kinase in psoriatic lesions and cultured human keratinocytes by epidermal growth factor receptor ligands. J Invest Dermatol 1997; 108:98-102.
3. Duncan JI. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J Invest Dermatol 1994; 102:84-8.
4. Meingassner JG, Stutz A. Anti-inflammatory effects of macrophylin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 1992; 99:486-9.
5. Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356:194-202.
6. Reitamo S, Spuls PI, Sassolas B et al. for the Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145:438-45.
7. Kahan BD. Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. J Am Soc Nephrol 1992; 2:S222-7.
8. Kligman AM, Christophers E. Preparation of isolated sheets of human stratum corneum. Arch Dermatol 1963; 88:702-5.
9. Holt DW, Lee T, Jones K, Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000; 46:1179-83.
10. Schaefer H, Stuttgen G. Absolute concentrations of an antimycotic agent, econazole, in the human skin after local application. Arzneimittelforschung 1976; 26:432-5.
11. Maleki S, Graves S, Becker S et al. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. Clin Ther 2000; 22 (Suppl. B): B25-37.
12. Ormerod AD, Dwyer CM, Weller R et al. A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. J Am Acad Dermatol 1997; 37:51-7.
13. Altman DG. Clinical trials. In: Practical Statistics for Medical Research. London: Chapman & Hall, 1991; 440-76.
14. Zonneveld IM, Rubins A, Jablonska S et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134:1101-2.
15. Remitz A, Reitamo S, Erkko P et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141:103-7.
16. Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139:992-6.
17. Luger T, van Leent EJ, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144:788-94.
18. Ruzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 37:816-21.
19. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol (Stockh) 2000; 80:451.
20. Lyon CC, Smith AJ, Beck MH et al. Parastomal pyoderma gangrenosum: dinical features and management. J Am Acad Dermatol 2000; 42:992-1002.
21. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139:755-7.
22. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140:338-42.
23. Schuppe H, Richter-Hintz D, Stierle HE et al. Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:105-6.
24. Casson DH, Eltumi M, Tomlin S et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47:436-40.
25. Hewitt CW, Black KS. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Transplant Proc 1996; 28:922-3.